Price
No data yet.
Social Signal Score
Company Profile
- CEO
- Lior Shaltiel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Beta
- 0.39
- Country
- CA
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
NRXBFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·17d ago·Neutral
NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in Boston CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in Boston
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets
View source ↗ - Newsglobenewswire.com·53d ago·Negative
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously reported functional recovery Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone's Clinical Pipeline and Planned Commercial Production The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone's Clinical Pipeline and Planned Commercial Production
View source ↗
Earnings
Wed, Nov 25(in 7 weeks)
Consensus estimate $-0.01 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 31$-0.02 vs $-0.02beat
- Mon, Jun 1$-0.02 vs $-0.02beat
- Wed, Nov 26$-0.02 vs $-0.02beat
- Wed, Aug 27$-0.02 vs $-0.02beat
- Tue, May 27$-0.02 vs $-0.02beat
- Wed, Nov 27$-0.06 vs $-0.03miss
Estimates and results for NRXBF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in NRXBF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.